Abpro Holdings, Inc.

ABPWW ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2024 FY2023
Revenue $183.0K $122.0K
Cost of Revenue — —
Gross Profit — —
Gross Margin — —
Operating Expenses
Research & Development $3.0M $4.3M
SG&A Expense $7.1M $7.6M
Operating Income $-9.9M $-11.7M
Operating Margin -5,421.3% -9,627.9%
Interest Expense — —
Pretax Income $-7.2M $-11.7M
Income Tax Expense — $1.2M
Net Income $-7.2M $2.8M
Net Margin -3,951.9% 2,312.7%
EPS (Basic) $-7.44 $-0.20
EPS (Diluted) $-7.44 $-0.20
Shares Outstanding (Basic) 2.3M 57.4M
Shares Outstanding (Diluted) 2.3M 57.4M
Dividends Per Share — —